Leap Therapeutics ( (LPTX) ) has released its Q2 earnings. Here is a breakdown of the information Leap Therapeutics presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Leap Therapeutics is a biotechnology company specializing in the development of targeted and immuno-oncology therapeutics, with a focus on monoclonal antibodies like sirexatamab and FL-501.
In its second-quarter 2025 earnings report, Leap Therapeutics highlighted significant strategic and financial developments, including a major workforce reduction and ongoing exploration of strategic alternatives to enhance shareholder value. The company also reported progress in its clinical trials, particularly the DeFianCe study involving sirexatamab.
Key financial metrics for the quarter showed a net loss of $16.6 million, a decrease from the previous year’s $20.4 million loss, attributed to reduced research and development expenses. The company implemented a 75% workforce reduction to further cut costs, incurring a $4.5 million restructuring charge. Additionally, Leap’s cash reserves stood at $18.1 million as of June 30, 2025.
Strategically, Leap is prioritizing corporate development for its key therapies, sirexatamab and FL-501, and is considering potential sales or partnerships. The company has engaged Raymond James & Associates as a financial advisor to assist in evaluating these strategic alternatives.
Looking ahead, Leap Therapeutics remains committed to maximizing shareholder value while advancing its therapeutic pipeline, with further updates anticipated in the coming weeks.